PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
PureTech Health has cleared an early hurdle in its pursuit of Sage Therapeutics, linking its oral prodrug of allopregnanolone to a nine-fold increase in the blood levels achieved by the unmodified molecule. Based on the data, the company is forging ahead with a view to starting a phase 1b/2a clinical trial next year.